Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptasel1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	SEP 01	New pricing for the Save Answers for SciFinder Wizard within STN Express with Discover!
NEWS	4	OCT 28	KOREAPAT now available on STN
NEWS	5	NOV 30	PHAR reloaded with additional data
NEWS	6	DEC 01	LISA now available on STN
NEWS	7	DEC 09	12 databases to be removed from STN on December 31, 2004
NEWS	8	DEC 15	MEDLINE update schedule for December 2004
NEWS	9	DEC 17	ELCOM reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	10	DEC 17	COMPUAB reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	11	DEC 17	SOLIDSTATE reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	12	DEC 17	CERAB reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	13	DEC 17	THREE NEW FIELDS ADDED TO IFIPAT/IFIUDB/IFICDB
NEWS	14	DEC 30	EPFULL: New patent full text database to be available on STN
NEWS	15	DEC 30	CAPLUS - PATENT COVERAGE EXPANDED
NEWS	16	JAN 03	No connect-hour charges in EPFULL during January and February 2005
NEWS	17	JAN 26	CA/CAPLUS - Expanded patent coverage to include the Russian Agency for Patents and Trademarks (ROSPATENT)
NEWS	18	FEB 10	STN Patent Forums to be held in March 2005

NEWS EXPRESS JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:49:47 ON 10 FEB 2005

=> file reg
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 15:49:54 ON 10 FEB 2005

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 9 FEB 2005 HIGHEST RN 828241-21-0
DICTIONARY FILE UPDATES: 9 FEB 2005 HIGHEST RN 828241-21-0

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Program Files\Stnexp\Queries\10808889b.str



chain nodes :
10 11 12 13 14
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
6-11 8-10 10-12 11-13 13-14
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9
exact/norm bonds :
2-7 3-9 6-11 7-8 8-9 8-10 10-12 11-13 13-14
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:Atom

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 full
FULL SEARCH INITIATED 15:50:09 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 308 TO ITERATE

100.0% PROCESSED 308 ITERATIONS 77 ANSWERS
SEARCH TIME: 00.00.01

L2 77 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 161.33 161.54

FILE 'CAPLUS' ENTERED AT 15:50:13 ON 10 FEB 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 10 Feb 2005 VOL 142 ISS 7
FILE LAST UPDATED: 9 Feb 2005 (20050209/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l2
L3 30 L2

=> d ibib abs hitstr tot
THE ESTIMATED COST FOR THIS REQUEST IS 148.20 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L3 ANSWER 1 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:60255 CAPLUS
DOCUMENT NUMBER: 140:105258
TITLE: Benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms
INVENTOR(S): Borisy, Alexis; Keith, Curtis; Foley, Michael A.; Stockwell, Brent R.; Gaw, Debra A.
PATENT ASSIGNEE(S): Combinatorx, Incorporated, USA
SOURCE: PCT Int. Appl., 79 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004006849	A2	20040122	WO 2003-US21984	20030715
WO 2004006849	A3	20040603		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-396151P P 20020715
OTHER SOURCE(S): MARPAT 140:105258
AB The invention features a method for treating a patient having a cancer or other neoplasm, by administering to the patient (i) a benzimidazole or a metabolite or analog thereof; and (ii) pentamidine or a metabolite or analog thereof simultaneously or within 14 days of each other in amts. sufficient to inhibit the growth of the neoplasm.
IT 90509-02-7, Luxabendazole
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(benzimidazole compound-pentamidine compound combinations for the treatment of neoplasms)
RN 90509-02-7 CAPLUS
CN Benzenesulfonic acid, 4-fluoro-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



L3 ANSWER 2 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:259734 CAPLUS
DOCUMENT NUMBER: 138:271683
TITLE: Preparation of 2-(acylamino)-5-(benzenesulfonyloxy)benzimidazole compounds and their use for the treatment of cancer
INVENTOR(S): Clerc, Francois; Hamy, Francois; Depaty, Isabelle; Angouillant-Boniface, Odile; Roesner, Manfred
PATENT ASSIGNEE(S): Aventis Pharma S.A., Fr.
SOURCE: Eur. Pat. Appl., 31 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1298125	A1	20030402	EP 2001-402460	20010926
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
WO 2003028721	A2	20030410	WO 2002-EP11353	20020926
WO 2003028721	A3	20031211		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1432417	A2	20040630	EP 2002-772370	20020926
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002012856	A	20040914	BR 2002-12856	20020926
US 2005014811	A1	20050120	US 2004-808889	20040325

PRIORITY APPLN. INFO.: EP 2001-402460 A 20010926
WO 2002-EP11353 W 20020926
OTHER SOURCE(S): MARPAT 138:271683
GI



I

AB New benzimidazole compds. of formula (I) [wherein R1 = 4-NH2, 4-alkylamino or cycloalkylamino eventually substituted with an acyl or its derivative, hydroxy, amino, alkoxy, heterocyclyl, or aryl group; R2 = (1) alkyl eventually substituted by amino, acid, acid derivative, alkoxy, aryl or OH groups, (2) arylalkyl eventually substituted by alkoxy, halogeno, amino,

L3 ANSWER 2 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
acid or acid derivs., (3) alkoxy eventually substituted by aryl, (4) amino, NHR3, or NR3R4 (wherein R3, R4 = H, alkyl, alkylaryl, aryl or together form an alkylene chain)] or pharmaceutically acceptable salts thereof, which are useful for treating cancer diseases, are prepd. These compds. I are inhibitors of cyclin-dependent kinases (CKDs, in particular CDK4) which are regulators for progression of the cell cycle at cell cycle checkpoints, and are effective in inhibiting the proliferation of neoplastic cells. Thus, 15.6 g 2-amino-5-(4-fluorophenylsulfonyloxy)nitro benzene were combined with 25 mL ethanolamine in 100 mL ethylene glycol in a round bottom flask and heated to reflux for 90 min to give, after workup, 15.5 g 2-amino-5-[4-(2-hydroxyethyl)aminophenylsulfonyloxy]nitrobe nzene (II). II (15.5 g) in 75 mL MeOH and 75 mL DMF were hydrogenated under atm. pressure with a catalytic amt. of Raney Nickel, filtered to remove the catalyst followed by washing the catalyst with MeOH. The filtrate and the washing were combined, concd. under reduced pressure, taken up in 150 mL MeOH and 30 mL glacial acetic acid, treated with 10.3 g 1,3-bis(methoxycarbonyl)-2-methyl-2-thiopseudourea, and heated to reflux with stirring for 3 h to give, after crystn. from methanol, 7.4 g Me 5-[4-(2-hydroxyethyl)aminophenylsulfonyloxy]benzimidazole-2-carbamate (III). III and Me 5-(4-aminophenylsulfonyloxy)benzimidazole-2-carbamate showed IC50 of 1.43 and 0.28 μM, resp., against CDK4/CyclionD1 kinase.
IT 503545-62-8P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of 2-(acylamino)-5-(benzenesulfonyloxy)benzimidazole compds. as inhibitors of cyclin-dependent kinases for treatment of cancer)
RN 503545-62-8 CAPLUS
CN Benzenesulfonic acid, 4-(1H-imidazol-1-yl)-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



IT 503545-56-0P 503545-58-2P 503545-60-6P
503545-63-9P 503545-64-0P 503545-65-1P
503545-66-2P 503545-67-3P 503545-68-4P
503545-69-5P 503545-70-8P 503545-71-9P
503545-72-0P 503545-73-1P 503545-74-2P
503545-75-3P 503545-76-4P 503545-78-6P
503545-80-0P, N-[5-[4-(1-Imidazolyl)phenylsulfonyloxy]-1H-benzimidazole-2-yl]succinamic acid methyl ester 503545-81-1P
503545-83-3P, N-[5-(4-Cyclopentylaminophenylsulfonyloxy)-1H-benzimidazole-2-yl]succinamic acid methyl ester 503545-84-4P,
4-[N-[5-(4-Cyclopentylaminophenylsulfonyloxy)-1H-benzimidazole-2-yl]carbamoyl]butanoic acid methyl ester 503545-85-5P,
N-[5-(4-Cyclopentylaminophenylsulfonyloxy)-1H-benzimidazole-2-yl]cyclopropanecarboxamide 503545-86-6P 503545-87-7P
503545-88-8P, N-[5-[4-(Imidazolyl)phenylsulfonyloxy]-1H-benzimidazol-2-yl]-N'-methylurea 503545-89-9P,
N-[5-(4-Cyclopentylaminophenylsulfonyloxy)-1H-benzimidazol-2-yl]-N'-methylurea 503545-90-2P, N-[5-(4-Cyclopentylaminophenylsulfonyloxy)-1H-benzimidazol-2-yl]-N',N'-dimethylurea 503545-91-3P,

L3 ANSWER 2 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
N-[5-(4-Cyclopentylaminophenylsulfonyloxy)-1H-benzimidazol-2-yl]-N'-cyclopropylurea 503545-92-4P, N-[5-(4-Cyclopentylaminophenylsulfonyloxy)-1H-benzimidazol-2-yl]-N'-isopropylurea 503545-93-5P, N-[5-(4-Cyclopentylaminophenylsulfonyloxy)-1H-benzimidazol-2-yl]-N'-butylurea 503545-94-6P,
N-[5-[4-(Imidazolyl)phenylsulfonyloxy]-1H-benzimidazol-2-yl]-N'-(2-fluorophenyl)urea 503545-95-7P, N-[5-(4-Cyclopentylaminophenylsulfonyloxy)-1H-benzimidazol-2-yl]-N'-(2-fluorophenyl)urea 503545-96-8P, N-[5-(4-Cyclopentylaminophenylsulfonyloxy)-1H-benzimidazole-2-yl]-N'-(3-methoxyphenyl)urea 503545-97-9P, N-[5-(4-Cyclopentylaminophenylsulfonyloxy)-1H-benzimidazol-2-yl]-N'-(4-methoxyphenyl)urea 503545-98-0P, N-[5-(4-Cyclopentylaminophenylsulfonyloxy)-1H-benzimidazol-2-yl]-N'-(4-chlorophenyl)urea 503545-99-1P, N-[5-(4-Cyclopentylaminophenylsulfonyloxy)-1H-benzimidazole-2-yl]-N'-(3-fluorophenyl)urea 503546-00-7P, N-[5-(4-Cyclopentylaminophenylsulfonyloxy)-1H-benzimidazol-2-yl]-N'-(3-chlorophenyl)urea 503546-01-8P, N-[5-(4-Cyclopentylaminophenylsulfonyloxy)-1H-benzimidazol-2-yl]-N'-isobutylurea 503546-02-9P, N-[5-(4-Cyclopentylaminophenylsulfonyloxy)-1H-benzimidazole-2-yl]-N'-(2-dimethylaminoethyl)urea 503546-03-0P,
N-[5-(4-Cyclopentylaminophenylsulfonyloxy)-1H-benzimidazole-2-yl]-N'-ethylurea 503546-04-1P, N-[5-(4-Cyclopentylaminophenylsulfonyloxy)-1H-benzimidazole-2-yl]-N'-(carboxymethyl)urea 503546-05-2P,
N-[5-[4-(Imidazolyl)phenylsulfonyloxy]-1H-benzimidazole-2-yl]-N'-(2-sulfoethyl)urea 503546-06-3P, N-[5-(4-Cyclopentylaminophenylsulfonyloxy)-1H-benzimidazole-2-yl]-N'-(2-methoxyethyl)urea 503546-07-4P 503546-08-5P,
N-[5-(4-Cyclopentylaminophenylsulfonyloxy)-1H-benzimidazole-2-yl]-N'-(2-pyridylmethyl)urea 503546-09-6P, N-[5-(4-Cyclopentylaminophenylsulfonyloxy)-1H-benzimidazole-2-yl]-N'-cyclobutylurea 503546-10-9P, N-[5-(4-Cyclopentylaminophenylsulfonyloxy)-1H-benzimidazole-2-yl]-N'-(4-pyridylmethyl)urea 503546-11-0P, N-[5-(4-Cyclopentylaminophenylsulfonyloxy)-1H-benzimidazole-2-yl]-N'-tert-butylurea
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 2-(acylamino)-5-(benzenesulfonyloxy)benzimidazole compds. as inhibitors of cyclin-dependent kinases for treatment of cancer)
RN 503545-56-0 CAPLUS
CN Benzenesulfonic acid, 4-[(2-hydroxyethyl)amino]-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 503545-58-2 CAPLUS
CN Benzenesulfonic acid, 4-[(4-hydroxybutyl)amino]-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)

Instant app



RN 503545-60-6 CAPLUS
CN Benzenesulfonic acid, 4-[(2-methoxyethyl)amino]-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 503545-63-9 CAPLUS
CN Benzenesulfonic acid, 4-[(2-pyridinylmethyl)amino]-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 503545-64-0 CAPLUS
CN Benzenesulfonic acid, 4-(ethylamino)-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 503545-65-1 CAPLUS
CN Benzenesulfonic acid, 4-[(aminoacetyl)amino]-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)





RN 503545-71-9 CAPLUS
CN Benzenesulfonic acid, 4-[(3-methoxypropyl)amino]-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 503545-72-0 CAPLUS
CN Benzenesulfonic acid, 4-(methylamino)-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 503545-73-1 CAPLUS
CN Benzenesulfonic acid, 4-[(2-sulfoethyl)amino]-, 1-[2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl] ester (9CI) (CA INDEX NAME)



RN 503545-74-2 CAPLUS
CN Benzenesulfonic acid, 4-amino-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)

RN 503545-66-2 CAPLUS
CN Benzenesulfonic acid, 4-[(2-hydroxy-1-methylethyl)amino]-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 503545-67-3 CAPLUS
CN Benzenesulfonic acid, 4-[(2-hydroxypropyl)amino]-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 503545-68-4 CAPLUS
CN Benzenesulfonic acid, 4-[(1-methylethyl)amino]-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 503545-69-5 CAPLUS
CN Benzenesulfonic acid, 4-[[1-(hydroxymethyl)propyl]amino]-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 503545-70-8 CAPLUS
CN Benzenesulfonic acid, 4-(butylamino)-, 2-[(methoxycarbonyl)amino]-1H-



RN 503545-75-3 CAPLUS
CN Benzenesulfonic acid, 4-[[2-(diethylamino)ethyl]amino]-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 503545-76-4 CAPLUS
CN Benzenesulfonic acid, 4-[[(tetrahydro-2-furanyl)methyl]amino]-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 503545-78-6 CAPLUS
CN Benzenesulfonic acid, 4-[(2-phenylethyl)amino]-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 503545-80-0 CAPLUS
CN Butanoic acid, 4-[[5-[[[4-(1H-imidazol-1-yl)phenyl]sulfonyl]oxy]-1H-benzimidazol-2-yl]amino]-4-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 503545-81-1 CAPLUS
CN Benzenesulfonic acid, 4-(cyclopentylamino)-, 2-[[[[(1,1-dimethylethoxy)carbonyl]amino]acetyl]amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 503545-83-3 CAPLUS
CN Butanoic acid, 4-[[5-[[[4-(cyclopentylamino)phenyl]sulfonyl]oxy]-1H-benzimidazol-2-yl]amino]-4-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 503545-84-4 CAPLUS
CN Pentanoic acid, 5-[[5-[[[4-(cyclopentylamino)phenyl]sulfonyl]oxy]-1H-benzimidazol-2-yl]amino]-5-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 503545-85-5 CAPLUS
CN Benzenesulfonic acid, 4-(cyclopentylamino)-, 2-[(cyclopropylcarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 503545-86-6 CAPLUS
CN Benzenesulfonic acid, 4-(cyclopentylamino)-, 2-[(methoxyacetyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 503545-87-7 CAPLUS
CN Benzenesulfonic acid, 4-(cyclopentylamino)-, 2-[[(dimethylamino)acetyl]amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 503545-88-8 CAPLUS
CN Benzenesulfonic acid, 4-(1H-imidazol-1-yl)-, 2-[[(methylamino)carbonyl]amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 503545-89-9 CAPLUS
CN Benzenesulfonic acid, 4-(cyclopentylamino)-, 2-[[(methylamino)carbonyl]amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 503545-90-2 CAPLUS
CN Benzenesulfonic acid, 4-(cyclopentylamino)-, 2-[[(dimethylamino)carbonyl]amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 503545-91-3 CAPLUS
CN Benzenesulfonic acid, 4-(cyclopentylamino)-, 2-[[(cyclopropylamino)carbonyl]amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 503545-92-4 CAPLUS
CN Benzenesulfonic acid, 4-(cyclopentylamino)-, 2-[[[(1-methylethyl)amino]carbonyl]amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 503545-93-5 CAPLUS
CN Benzenesulfonic acid, 4-(cyclopentylamino)-, 2-[[(butylamino)carbonyl]amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 503545-94-6 CAPLUS
CN Benzenesulfonic acid, 4-(1H-imidazol-1-yl)-, 2-[[[(2-fluorophenyl)amino]carbonyl]amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 503545-95-7 CAPLUS
CN Benzenesulfonic acid, 4-(cyclopentylamino)-, 2-[[[(2-fluorophenyl)amino]carbonyl]amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 503545-96-8 CAPLUS
CN Benzenesulfonic acid, 4-(cyclopentylamino)-, 2-[[[(3-methoxyphenyl)amino]carbonyl]amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 503545-97-9 CAPLUS
CN Benzenesulfonic acid, 4-(cyclopentylamino)-, 2-[[[(4-methoxyphenyl)amino]carbonyl]amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 503545-98-0 CAPLUS
CN Benzenesulfonic acid, 4-(cyclopentylamino)-, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 503545-99-1 CAPLUS
CN Benzenesulfonic acid, 4-(cyclopentylamino)-, 2-[[[(3-fluorophenyl)amino]carbonyl]amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 503546-00-7 CAPLUS
CN Benzenesulfonic acid, 4-(cyclopentylamino)-, 2-[[[(3-chlorophenyl)amino]carbonyl]amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 503546-01-8 CAPLUS
CN Benzenesulfonic acid, 4-(cyclopentylamino)-, 2-[[[(2-methylpropyl)amino]carbonyl]amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 503546-02-9 CAPLUS
CN Benzenesulfonic acid, 4-(cyclopentylamino)-, 2-[[[[2-(dimethylamino)ethyl]amino]carbonyl]amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 503546-07-4 CAPLUS
CN Benzenesulfonic acid, 4-(cyclopentylamino)-, 2-[[[[4-(dimethylamino)phenyl]amino]carbonyl]amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 503546-08-5 CAPLUS
CN Benzenesulfonic acid, 4-(cyclopentylamino)-, 2-[[[(2-pyridinylmethyl)amino]carbonyl]amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 503546-09-6 CAPLUS
CN Benzenesulfonic acid, 4-(cyclopentylamino)-, 2-[[(cyclobutylamino)carbonyl]amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 503546-10-9 CAPLUS
CN Benzenesulfonic acid, 4-(cyclopentylamino)-, 2-[[[(4-pyridinylmethyl)amino]carbonyl]amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 503546-03-0 CAPLUS
CN Benzenesulfonic acid, 4-(cyclopentylamino)-, 2-[[(ethylamino)carbonyl]amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 503546-04-1 CAPLUS
CN Glycine, N-[[[5-[[[4-(cyclopentylamino)phenyl]sulfonyl]oxy]-1H-benzimidazol-2-yl]amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 503546-05-2 CAPLUS
CN Benzenesulfonic acid, 4-(1H-imidazol-1-yl)-, 2-[[[(2-sulfoethyl)amino]carbonyl]amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 503546-06-3 CAPLUS
CN Benzenesulfonic acid, 4-(cyclopentylamino)-, 2-[[[(2-methoxyethyl)amino]carbonyl]amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 503546-11-0 CAPLUS
CN Benzenesulfonic acid, 4-(cyclopentylamino)-, 2-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



IT **503545-77-5P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(reactant; preparation of
2-(acylamino)-5-(benzenesulfonyloxy)benzimidazole
compds. as inhibitors of cyclin-dependent kinases for treatment of cancer)

RN 503545-77-5 CAPLUS
CN Benzenesulfonic acid, 4-(cyclopentylamino)-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:754210 CAPLUS
DOCUMENT NUMBER: 137:273177
TITLE: Method for treatment of cancer and compositions for use therein
INVENTOR(S): Morris, David Lawrence; Pourgholami, Mohammad Hossein
PATENT ASSIGNEE(S): Unisearch Limited, Australia
SOURCE: PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002076454	A1	20021003	WO 2002-AU339	20020320
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2441768	AA	20021003	CA 2002-2441768	20020320
EP 1379242	A1	20040114	EP 2002-713920	20020320
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004525140	T2	20040819	JP 2002-574969	20020320

PRIORITY APPLN. INFO.:
US 2001-278435P P 20010326
CA 2001-2342472 A 20010330
WO 2002-AU339 W 20020320

OTHER SOURCE(S): MARPAT 137:273177
GI



I

AB The invention discloses the use of compound I [R1 = H, alkyl, alkenyl, alkenylalkyl, cycloalkyl, cycloalkylalkyl, cycloalkenylalkyl, aryl etc. ; R2 = H, alkyl; R3 = H, alkyl, alkenyl, alkenylalkyl, cycloalkyl, cycloalkylalkyl, cycloalkenylalkyl, aryl, arylalkyl etc.] for the treatment of a tumor in a subject.

IT **90509-02-7**, Luxabendazole
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treatment of cancer and compns. for use therein)

RN 90509-02-7 CAPLUS
CN Benzenesulfonic acid, 4-fluoro-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)

L3 ANSWER 3 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:574927 CAPLUS
DOCUMENT NUMBER: 137:119655
TITLE: Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
INVENTOR(S): Borisy, Alexis; Keith, Curtis; Foley, Michael A.; Stockwell, Brent R.
PATENT ASSIGNEE(S): Combinatorx, Incorporated, USA
SOURCE: PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002058697	A1	20020801	WO 2002-US1707 *	20020122
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002165261	A1	20021107	US 2001-768870	20010124
US 6693125	B2	20040217		
EP 1363625	A1	20031126	EP 2002-709117	20020122
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2004063769	A1	20040401	US 2003-677664	20031002

PRIORITY APPLN. INFO.:
US 2001-768870 A1 20010124
WO 2002-US1707 W 20020122

OTHER SOURCE(S): MARPAT 137:119655
AB The invention features a method for treating a patient having a cancer or other neoplasm, by administering to the patient (i) a benzimidazole or a metabolite or analog thereof; and (ii) pentamidine or a metabolite or analog thereof simultaneously or within 14 days of each other in amts. sufficient to inhibit the growth of the neoplasm.

IT **90509-02-7**, Luxabendazole
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(drug combinations for treatment of neoplastic disorders)

RN 90509-02-7 CAPLUS
CN Benzenesulfonic acid, 4-fluoro-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

L3 ANSWER 5 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1998:476162 CAPLUS
DOCUMENT NUMBER: 129:197544
TITLE: Pharmacokinetics of intravenous luxabendazole in rabbits: influence of the enterohepatic circulation
AUTHOR(S): Alvarez-Bujidos, Lucia; Ortiz, Ana I.; Molina-Martinez, Irene T.; Cubria, Carlos; Ordonez, David
CORPORATE SOURCE: Departamento de Fisiologia, Farmacologia y Toxicologia, Facultad de Veterinaria, Universidad de Leon, Leon, E-24071, Spain
SOURCE: Biopharmaceutics & Drug Disposition (1998), 19(5), 341-347
CODEN: BDDID8; ISSN: 0142-2782
PUBLISHER: John Wiley & Sons Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Luxabendazole (LBZ) is a new benzimidazole carbamate chemotherapeutic agent, which has proved to be very effective against adult and immature stages of the major gastrointestinal nematodes, trematodes and cestodes. While information on the efficacy of LBZ in several animal species is available, there seems to be no published information describing the disposition kinetics in any of them. As a part of the clin. development of luxabendazole, the pharmacokinetics of a single i.v. dose was investigated in parasite-free rabbits. Serial blood samples were collected at timed intervals for 12 h following administration of the dose, and concns. in plasma were determined by a sensitive and specific HPLC method. Published data on LBZ point to the possible existence of an enterohepatic cycle (EHC), and so, it seemed appropriate to carry out two different forms of test. In the first, the possibility of intestinal resorption of LBZ excreted via the bile was allowed for (Treatment 1), while in the second it was interrupted by the oral administration of activated charcoal (Treatment 2). In both cases the animals were given a single dose of 10 mg kg-1 of LBZ i.v. (i.v). Comparison of the areas under the curve (AUCs) of LBZ concns. in plasma samples taken from the animals receiving each treatment showed significant difference ($p < 0.05$). The given dose (10 mg kg-1) was converted in Treatment 1 to an ED of 13.9 mg kg-1 through recycling of LBZ. With Treatment 2 a bicompartmental distribution model for this drug was confirmed, together with high apparent distribution vols.: Vc = 1.87 L kg-1, and Vβ = 7.09 L kg-1.

IT **90509-02-7**, Luxabendazole
RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(pharmacokinetics of i.v. luxabendazole in rabbits and influence of the enterohepatic circulation)

RN 90509-02-7 CAPLUS
CN Benzenesulfonic acid, 4-fluoro-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

L3 ANSWER 6 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1998:455343 CAPLUS
DOCUMENT NUMBER: 129:58835
TITLE: Veterinary formulation of benzimidazole derivative endoparasiticides for topical application
INVENTOR(S): Derrieu, Guy; Piat, Jean Philippe Robert Charles; Pougnas, Jean Luc
PATENT ASSIGNEE(S): Virbac S. A., Fr.
SOURCE: Fr. Demande, 24 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
→	FR 2755824	A1	19980522	FR 1996-14068	19961119
	FR 2755824	B1	19990108		

PRIORITY APPLN. INFO.: FR 1996-14068 19961119

AB The title formulations comprise a benzimidazole endoparasiticide (oxfendazole, albendazole, albendazole sulfoxide, fenbendazole, flubendazole, mebendazole, thiabendazole, cambendazole, etc.) a nonaq. vehicle, a nonaq. cosolvent, a nonionic surfactant and a polymer. The nonaq. vehicle is DMSO, decyl Me sulfoxide, N,N-dimethylacetamide, 2-pyrrolidone or N-methylpyrrolidone. The benzimidazole derivs. are i.n the form of real soluble in the formulation.

IT **90509-02-7**, Luxabendazole
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(veterinary formulation of benzimidazole derivative endoparasiticides for topical application)

RN 90509-02-7 CAPLUS
CN Benzenesulfonic acid, 4-fluoro-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



L3 ANSWER 7 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1998:342251 CAPLUS
DOCUMENT NUMBER: 129:103768
TITLE: Relations between the structure and embryotoxic action of nitrogen- and sulfur-containing organic compounds
AUTHOR(S): Tyurina, L. A.; Zul'karnaev, T. R.; Solominova, T. S.; Tyurin, A. A.; Shaimukhametova, R. Kh.; Pilyugin, V. S.; Khaliullin, F. A.
CORPORATE SOURCE: Nauchno-Issled. Tekhnol. Inst. Gerbitsidov i Regulyatorov Rosta Rastenii, Ufa, Russia
SOURCE: Khimiko-Farmatsevticheskii Zhurnal (1998), 32(2), 21-27
CODEN: KHFZAN; ISSN: 0023-1134
PUBLISHER: Izdatel'stvo Folium
DOCUMENT TYPE: Journal
LANGUAGE: Russian

AB The authors presented the results of the anal. of the structure-embryotoxicity relationships based on the use of the computer program SARD. Preparation of the novel anthelmintic biphen (VK-40) is described.

IT **90509-02-7**
RL: ADV (Adverse effect, including toxicity); PRP (Properties); BIOL (Biological study)
(relations between the structure and embryotoxic action of nitrogen- and sulfur-containing organic compds.)

RN 90509-02-7 CAPLUS
CN Benzenesulfonic acid, 4-fluoro-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



L3 ANSWER 8 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1997:795227 CAPLUS
DOCUMENT NUMBER: 128:110279
TITLE: A new in vitro assay of benzimidazole activity against adult Oesophagostomum dentatum
AUTHOR(S): Petersen, Mads Bjelke; Friis, Christian; Bjorn, Henrik
CORPORATE SOURCE: Department of Pharmacology and Pathobiology, Copenhagen, DK-1870, Den.
SOURCE: International Journal for Parasitology (1997), 27(11), 1333-1339
CODEN: IJPYBT; ISSN: 0020-7519
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A new in vitro assay of benzimidazole activity against adult Oesophagostomum dentatum is described. The method is based on the ability of O. dentatum to migrate through polyamide nets after exposure to various concns. of benzimidazole. To determine an appropriate mesh size, control worms and worms exposed to 10 μM oxfendazole for 24 h were allowed to migrate through nets with various mesh sizes (300-500 μm) for up to 1 h. A mesh size of 350 μm and migration periods of 10, 20 and 30 min were selected. Exposure to oxfendazole at 10 μM for 24, 48 and 72 h inhibited the migration in a time-dependent manner. After 72 h of exposure and with a 20-min migration period, the EC50 of oxfendazole for O. dentatum was 0.564 μM. In further studies the activities of albendazole sulfoxide, albendazole, cambendazole, fenbendazole, flubendazole, luxabendazole, mebendazole, oxfendazole, oxibendazole, parbendazole and thiabendazole were compared. The worms were exposed to each drug at two concns. (0.1 and 3.16 μM) for 72 h. At 3.16 μM there were no significant differences in the activity of the drugs. At 0.1 μM significant differences in activity were found. Albendazole sulfoxide and oxfendazole were poor inhibitors of migration compared with their parent compds., albendazole and fenbendazole.

IT 90509-02-7, Luxabendazole
RL: ANT (Analyte); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(in vitro assay of benzimidazole activity against adult Oesophagostomum dentatum)
RN 90509-02-7 CAPLUS
CN Benzenesulfonic acid, 4-fluoro-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 9 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

L3 ANSWER 9 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1997:737711 CAPLUS
DOCUMENT NUMBER: 128:43392
TITLE: Pharmacokinetics of luxabendazole after oral and intravenous administration to sheep
AUTHOR(S): Ortiz, Ana I.; Alvarez-Bujidos, Lucia; Ferre, Ignacio; Ordonez, David
CORPORATE SOURCE: Departamento de Fisiologia, Farmacologia y Toxicologia, Facultad de Veterinaria, Universidad de Leon, Leon, E-24071, Spain
SOURCE: American Journal of Veterinary Research (1997), 58(11), 1263-1266
CODEN: AJVRAH; ISSN: 0002-9645
PUBLISHER: American Veterinary Medical Association
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The authors determined the pharmacokinetics of luxabendazole after oral and IV administration to 7 clin. normal female Merino sheep between 9 and 12 mo old. Pharmacokinetics were determined after oral and IV administration of luxabendazole at a dose of 10 mg/kg of body weight Serial blood samples were collected for 56 h after administration. Plasma concns. of luxabendazole were determined by high-pressure liquid chromatog. After IV administration, elimination of luxabendazole was slow, with a mean half-life of 8.72 h. Mean steady-state volume of distribution and mean distribution volume during the elimination phase were 3.18 and 3.10 L/kg, resp. Mean clearance was 0.24 L/kg·h, and mean area under the concentration-time curve was 41.89 mg·h/L. After oral administration, luxabendazole was slowly absorbed from the gastrointestinal tract. Mean absorption half-life was 2.26 h. Peak plasma concentration was 0.50 μg/mL and was detected 14 to 16 h after drug administration. Mean area under the concentration-time curve was 12.03 mg·h/L. Mean bioavailability was 29%. The results suggest that luxabendazole is moderately absorbed from the gastrointestinal tract in sheep, is widely distributed into extravascular compartments, and is cleared slowly. Determination of pharmacokinetic parameters is the first step in determining a safe and efficacious dosage regimen for luxabendazole in sheep.

IT 90509-02-7, Luxabendazole
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(luxabendazole pharmacokinetics after oral and i.v. administration to sheep)
RN 90509-02-7 CAPLUS
CN Benzenesulfonic acid, 4-fluoro-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 10 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1997:655430 CAPLUS
DOCUMENT NUMBER: 127:298526
TITLE: Method for promoting hair, nail, and skin keratinization
INVENTOR(S): Schick, Mary P.
PATENT ASSIGNEE(S): Schick, Mary P., USA
SOURCE: PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9735540	A1	19971002	WO 1997-US3919	19970313
W: CN, JP				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5861142	A	19990119	US 1996-621473	19960325
EP 896517	A1	19990217	EP 1997-915037	19970313
R: AT, CH, DE, GB, LI, LU, IE				

PRIORITY APPLN. INFO.: US 1996-621473 A 19960325
WO 1997-US3919 W 19970313

AB A method for promoting keratinization of the hair, nails, and skin on the body of an animal or human comprises administration of a therapeutic amount of a benzimidazole either systemically or directly to the site on the body at which keratinization is desired. The method is useful for the treatment of a wide variety of hair loss disorders in humans such as alopecia, is useful for the treatment of hair loss disorders in animals, is useful for enhancing the strength and length of fingernails and toenails in humans, and is useful for enhancing the strength and length of claws, horns, hooves and antlers in animals. The method is also useful for the topical treatment of fungal infections, for skin replacement or grafting, and for wound healing. Oral and topical administration of fenbendazole to hairless rats resulted in promoting hair growth on the face, lateral thorax and lateral abdomen by day 7.

IT 90509-02-7, Luxabendazole
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(benzimidazoles for promoting keratinization of hair and nails and skin)
RN 90509-02-7 CAPLUS
CN Benzenesulfonic acid, 4-fluoro-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



L3 ANSWER 11 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1996:673603 CAPLUS
DOCUMENT NUMBER: 125:316332
TITLE: Effects of luxabendazole on the intestinal wall of Fasciola hepatica (L.)
AUTHOR(S): Gorchilova, L.; Stoitsova, S.; Poljakova-Krusteva, O.; Spaldonova, R.
CORPORATE SOURCE: Inst. Experimental pathol. Parasitol., Sofia, 1113, Bulg.
SOURCE: Dokladi na Bulgarskata Akademiya na Naukite (1996), 49(1), 101-103
CODEN: DBANEH; ISSN: 0861-1459
PUBLISHER: Izdatelstvo na Bulgarskata Akademiya na Naukite
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Rats exptl. infected with F. hepatica were treated with luxabendazole (5, 10, or 20 mg/kg). Luxabendazole had a significant effect on the structural and functional characteristics of the intestinal wall of the fluke. Examination of cell pathol. showed blebbing or disruption of the microvillar membrane, an increase in autophagolysis, and development of necrotic zones. The damage was already marked 48 h after treatment and increased with time, being most severe at 14 days post treatment. Some does-related differences in the extent of damage was seen at the shortest post-treatment interval examined (48 h), but was insignificant at the longer post-treatment intervals (7 or 14 days).
IT **90509-02-7**, Luxabendazole
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(effects of luxabendazole on intestinal wall of Fasciola hepatica (L.))
RN 90509-02-7 CAPLUS
CN Benzenesulfonic acid, 4-fluoro-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



L3 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1996:97494 CAPLUS
DOCUMENT NUMBER: 124:193439
TITLE: Bacterial mutagenic evaluation of luxabendazole, a new broad spectrum anthelmintic, with the Salmonella typhimurium His- and the Escherichia coli Trup- reversion tests
AUTHOR(S): Ortiz, Ana I.; Pollastrini, M. Teresa; Barea, Marta; Ordonez, David
CORPORATE SOURCE: Fac. Veterinaria, Univ. Leon, Leon, 24071, Spain
SOURCE: Mutagenesis (1996), 11(1), 27-31
CODEN: MUTAEX; ISSN: 0267-8357
PUBLISHER: Oxford University Press
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Luxabendazole is a new benzimidazole carbamate chemotherapeutic agent, which has proved to be effective against adult and immature stages of the major gastrointestinal nematodes, trematodes and cestodes. The mutagenic properties of Luxabendazole were investigated in the in vitro Ames Salmonella and E. coli tests. The product was tested at concns. of 0.5, 5, 50, 500, 1250 and 2500 μg/plate in the TA1535, TA1538, TA98 and TA100 strains of Salmonella typhimurium, and 0.5, 5, 50 and 500 μg/plate in the WP2, WP2 urvA- and its pKM 101-containing derivative CM891 (WP2
urvA- pKM1010) strains of Escherichia coli, with and without S9 microsomal activation (post-mitochondrial liver fraction from Wistar rats pretreated with Aroclor). Pos. and neg. controls were included in each experiment
From
the present study it can be concluded that Luxabendazole, over a dose range of 0.5-2500 μg/plate, is unlikely to present a mutagenic hazard, as demonstrated by the Ames test.
IT **90509-02-7**, Luxabendazole
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(bacterial mutagenic evaluation of luxabendazole, a new broad spectrum anthelmintic, with the Salmonella typhimurium His- and the Escherichia coli Trup- reversion tests)
RN 90509-02-7 CAPLUS
CN Benzenesulfonic acid, 4-fluoro-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



L3 ANSWER 13 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1995:831958 CAPLUS
DOCUMENT NUMBER: 123:275220
TITLE: Development of a quantitative structure-activity (QSAR) model, based on molecular connectivity indexes for benzimidazole-type anthelmintics
AUTHOR(S): Tello, Miriam; Corredor, Claudia C.
CORPORATE SOURCE: Facultad de Ciencias, Universidad Nacional, Santafe de Bogata, 14490, Colombia
SOURCE: Revista Colombiana de Ciencias Quimico-Farmaceuticas (1995), 23, 32-41
CODEN: RCQFAQ; ISSN: 0034-7418
PUBLISHER: Universidad Nacional de Colombia, Facultad de Ciencias, Departamento de Farmacia
DOCUMENT TYPE: Journal
LANGUAGE: Spanish
AB In the present work a quant. relationship between the anthelmintic action and the chemical structure of benzimidazols 2-methylcarbamate 5(6) substituted group was established, using linear regression anal. and statistical criteria for the selection of the best equation. The chemical structure was quantified by the mol. connectivity method. The regression anal. shows a high correlation between the activity of 31 benzimidazols. The mol. connectivity, a theor. parameter for quantification of the chemical structure, based on the graphos theory helps to explain the dependence of the activity on the substituting groups in the 5 position. The math. model proposed helps to predict the activity of mols. structurally related. Six new mols. of a group of nine showed good activity according to this model.
IT **90509-02-7**, Luxabendazole
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(development of a quant. structure-activity model based on mol. connectivity indexes for benzimidazole-type anthelmintics)
RN 90509-02-7 CAPLUS
CN Benzenesulfonic acid, 4-fluoro-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



L3 ANSWER 14 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1995:444225 CAPLUS
DOCUMENT NUMBER: 122:205174
TITLE: Synergistic anthelmintic compositions
INVENTOR(S): Boray, Joseph Coloman
PATENT ASSIGNEE(S): Australian National University, USA; State of New South Wales
SOURCE: PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9428887	A1	19941222	WO 1994-AU315	19940614
W: AU, NZ, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9469654	A1	19950103	AU 1994-69654	19940614
AU 679753	B2	19970710		
ZA 9404191	A	19950208	ZA 1994-4191	19940614
EP 710105	A1	19960508	EP 1994-918238	19940614
EP 710105	B1	20030730		
R: BE, CH, DE, ES, FR, GB, IE, IT, LI				

PRIORITY APPLN. INFO.: AU 1993-9339 A 19930615
WO 1994-AU315 W 19940614
AB A method for the control of Fasciola spp. and other helminths in an animal, particularly a ruminant animal, comprises the administration to the animal of at least two anthelmintic-active drugs, optionally together with an acceptable carrier or diluent, to exert a synergistic effect in the animal. The anthelmintic-active drugs are selected from the group consisting of halogenated monophenols or bisphenols, salicylanilides, benzene sulfonamides, halogenated benzimidazoles, benzimidazoles and benzimidazole carbamates. Synergistic compns. comprising these anthelmintic-active drugs are also disclosed. Efficacy of synergistic combinations against F. hepatica are reported.
IT **90509-02-7**, Luxabendazole **161799-20-8** **161829-01-2** **161829-02-3**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anthelmintic synergistic combinations)
RN 90509-02-7 CAPLUS
CN Benzenesulfonic acid, 4-fluoro-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 161799-20-8 CAPLUS
CN Benzenesulfonic acid, 4-fluoro-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester, mixt. with 4-amino-6-(trichloroethenyl)-1,3-benzenedisulfonamide (9CI) (CA INDEX NAME)

CM 1

CRN 90509-02-7
CMF C15 H12 F N3 O5 S



CM 2

CRN 60200-06-8
CMF C8 H8 C13 N3 O4 S2



RN 161829-01-2 CAPLUS
CN Benzenesulfonic acid, 4-fluoro-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester, mixt. with 5-chloro-6-(2,3-dichlorophenoxy)-2-(methylthio)-1H-benzimidazole (9CI) (CA INDEX NAME)

CM 1

CRN 90509-02-7
CMF C15 H12 F N3 O5 S



CM 2

CRN 68786-66-3
CMF C14 H9 C13 N2 O S



RN 161829-02-3 CAPLUS
CN Benzenesulfonic acid, 4-fluoro-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester, mixt. with N-[5-chloro-4-[(4-chlorophenyl)cyanomethyl]-2-methylphenyl]-2-hydroxy-3,5-diiodobenzamide (9CI) (CA INDEX NAME)

CM 1

CRN 90509-02-7
CMF C15 H12 F N3 O5 S



CM 2

CRN 57808-65-8
CMF C22 H14 C12 I2 N2 O2



ACCESSION NUMBER: 1995:364211 CAPLUS
DOCUMENT NUMBER: 122:114945
TITLE: controlled-release antiparasitic compositions
INVENTOR(S): Hennessy, Desmond Ronald; Ashes, John Richard; Scott, Trevor William; Gulati, Suresh Kumar; Steel, John Winston
PATENT ASSIGNEE(S): Commonwealth Scientific and Industrial Research Organization, Australia; Meat Research Corp.
SOURCE: PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9427598	A1	19941208	WO 1994-AU272	19940524
W: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KG, KP, KR, KZ, LK, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2163455	AA	19941208	CA 1994-2163455	19940524
AU 9467902	A1	19941220	AU 1994-67902	19940524
AU 687062	B2	19980219		
BR 9406627	A	19960206	BR 1994-6627	19940524
EP 705101	A1	19960410	EP 1994-916095	19940524
EP 705101	B1	20011219		
R: DE, ES, FR, GB, IT				
ES 2170099	T3	20020801	ES 1994-916095	19940524
ZA 9403647	A	19950127	ZA 1994-3647	19940525
US 5840324	A	19981124	US 1996-549755	19960313
PRIORITY APPLN. INFO.:			AU 1993-9030 A	19930526
			WO 1994-AU272 W	19940524

AB The delivery of anti-parasitic agents to ruminant animals in a controlled manner to enable the agent to have maximum effect on the parasite for longer times than is possible with conventional formulations is described. The compns. comprise a benzimidazole, macrocyclic lactone, organophosphate, salicylanilide/substituted phenol, tetramisole or pyrimidine anti-parasitic agent, dispersed in a medium the solubility characteristics of which are such as to ensure that, following oral administration, controlled amts. of the anti-parasitic agent become available to the parasite, either directly or by absorption into the ruminant blood plasma, during passage of the composition through the rumen, the abomasum and the intestine. A 3-stage release antiparasitic formulation was prepared from benzimidazole, vegetable oil, emulsification with caseins, freeze-drying and treatment with formalin.

IT 90509-02-7, Luxabendazole
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(controlled-release antiparasitic compns.)

RN 90509-02-7 CAPLUS
CN Benzenesulfonic acid, 4-fluoro-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



L3 ANSWER 16 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1995:342640 CAPLUS
DOCUMENT NUMBER: 122:122569
TITLE: Effects of luxabendazole on the spermatogenesis and ultrastructure of the spermatozoa of Fasciola hepatica
AUTHOR(S): Stoitsova, S. R.; Gorchilova, L. N.
CORPORATE SOURCE: Institute Parasitology, Bulgarian Academy Sciences, Sofia, 1113, Bulg.
SOURCE: Doklady na Bulgarskata Akademiya na Naukite (1993), 46(9), 97-9
CODEN: DBANEH; ISSN: 0861-1459
PUBLISHER: Izdatelstvo na Bulgarskata Akademiya na Naukite
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Forty-eight h after administration of luxabendazole (5 or 10 mg/kg) to rats exptl. infected with Fasciola hepatica, the occurrence of abnormal spermatozoa of the F. hepatica was quite frequent. These results may explain the reduced fecundity of luxabendazole-treated flukes.
IT 90509-02-7, Luxabendazole
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(effects of luxabendazole on the spermatogenesis and ultrastructure of spermatozoa of Fasciola hepatica in relation to anthelmintic activity)
RN 90509-02-7 CAPLUS
CN Benzenesulfonic acid, 4-fluoro-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



L3 ANSWER 17 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1995:218095 CAPLUS
DOCUMENT NUMBER: 122:272
TITLE: The intestinal absorption of luxabendazole in rats
AUTHOR(S): del Estal, J. L.; Alvarez-Bujidos, M. L.; Balana Fouce, R.; Ordonez, D.; Prieto, J. G.
CORPORATE SOURCE: Dept. Fisiologia, Univ. Leon, Leon, E-24071, Spain
SOURCE: Journal of Pharmaceutical and Biomedical Analysis (1994), 12(11), 1471-14
CODEN: JPBADA; ISSN: 0731-7085
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Intestinal absorption of luxabendazole in rats may be due to a kinetic mechanism of simple diffusion and therefore no energy-dependent saturable kinetics are involved. Kinetic consts. of 2 structural analogs (albendazole and mebendazole) were also determined and the consts. compared with octanol/water partition coeffs.
IT 90509-02-7, Luxabendazole
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(intestinal absorption of)
RN 90509-02-7 CAPLUS
CN Benzenesulfonic acid, 4-fluoro-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



L3 ANSWER 18 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1994:612991 CAPLUS
DOCUMENT NUMBER: 121:212991
TITLE: Synergistic compositions containing benzimidazole anthelmintics and methylenedioxyphenyl compounds
INVENTOR(S): Benchaoui, Hafid Abdelaali; Mckellar, Quintin Archibald
PATENT ASSIGNEE(S): University of Glasgow, UK
SOURCE: PCT Int. Appl., 23 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9417798	A1	19940818	WO 1994-GB193	19940202
W: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2153785	AA	19940818	CA 1994-2153785	19940202
AU 9459744	A1	19940829	AU 1994-59744	19940202
AU 675826	B2	19970220		
ZA 9400718	A	19950802	ZA 1994-718	19940202
EP 682518	A1	19951122	EP 1994-905775	19940202
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
BR 9406244	A	19960206	BR 1994-6244	19940202
CN 1117267	A	19960221	CN 1994-191091	19940202
JP 09500089	T2	19970107	JP 1994-517771	19940202
RU 2121837	C1	19981120	RU 1995-120362	19940202
US 5744494	A	19980428	US 1995-495486	19950725
PRIORITY APPLN. INFO.:			GB 1993-2107 A	19930203
			WO 1994-GB193 W	19940202

AB The anthelmintic efficacy in animals and humans of a benzimidazole such as fenbendazole (I), is potentiated by use with piperonyl butoxide (II) or other methylenedioxyphenyl synergists. Lambs were fed an oral dose of 6000 I-resistant Ostertagia circumcincta and 28 days after infection animals were treated with 5mg I/kg and 63 mg II/kg and were killed on day 35 and nematode egg nos. were determined in feces. Neither I or II alone significantly reduced the number of O. circumcincta in the abomasa of lambs while the combination of I and II reduced the number by 84.9%.
IT 90509-02-7D, Luxabendazole, mixts. with methylenedioxyphenyl derivs.
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(synergistic anthelmintic compns.)
RN 90509-02-7 CAPLUS
CN Benzenesulfonic acid, 4-fluoro-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)

L3 ANSWER 18 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L3 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1994:548399 CAPLUS
DOCUMENT NUMBER: 121:148399
TITLE: Effects of luxabendazole on the tegument of Fasciola hepatica
AUTHOR(S): Stoitsova, S.R.; Gorchilova, L.N.
CORPORATE SOURCE: Inst. Parasitol., Sofia, 1113, Bulg.
SOURCE: Journal of Helminthology (1994), 68(1), 73-80
CODEN: JOHLAT; ISSN: 0022-149X
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The effects in vivo of 5, 10, and 20 mg/kg of luxabendazole (LBZ) on the tegument of Fasciola hepatica have been examined 48 h, 7 days and 14 days post-treatment of exptl.-infected rats. As early as 48 h post-treatment, the drug is shown to provoke significant damage to the tegument. The pathol. phenomena characterizing LBZ damage are blebbing of the apical plasmalemma, formation of microvillus-like projections over the free surface, swelling of the basal infolds and stimulation of autophagy. The spines are often fractured; the tegument in the vicinity of spines seems more strongly altered than that in other foci. The basal layer is often changed, from increase of electron d. to lack of integrity with the apical cytoplasm. The progress of the ultrastructural damage with time is not expressed. However, cytochem. data show that at longer post-treatment intervals the surface-coat structure becomes irregular and patches of ruthenium red pos. material of variable thickness are focally accumulated. Only a slight dose-effect is noted 48 h after LBZ application when the alterations provoked by 5 mg/kg are less evident than those by 10 and 20 mg/kg.

IT 90509-02-7, Luxabendazole
RL: BIOL (Biological study)
(tegument damage by, in Fasciola hepatica)

RN 90509-02-7 CAPLUS
CN Benzenesulfonic acid, 4-fluoro-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



L3 ANSWER 20 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1994:298627 CAPLUS
DOCUMENT NUMBER: 120:298627
TITLE: Process for preparing methyl [5-(4-fluorobenzenesulfonyloxy)benzimidazol-2-yl]carbamate [dabendazole]
INVENTOR(S): Novacek, Alois; Korner, Jaroslav; Hromas, Josef; Brozek, Jiri; Danek, Jaroslav
PATENT ASSIGNEE(S): Chemopharma, Czech.
SOURCE: Czech., 4 pp.
CODEN: CZXXA9
DOCUMENT TYPE: Patent
LANGUAGE: Czech
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
→ CS 277240	B6	19921216	CS 1990-4247	19900831
PRIORITY APPLN. INFO.:			CS 1990-4247	19900831

OTHER SOURCE(S): CASREACT 120:298627
GI



I

II

AB The anthelmintic dabendazole (I) is prepared by reduction of 2-amino-5-(4-fluorobenzenesulfonyloxy)nitrobenzene (II) with Fe or Zn in dilute AcOH in EtOH, followed by cyclocondensation of the resultant 1,2-diamino-4-(4-fluorophenylsulfonyloxy)benzene with MeOCONHCN (III) in situ. Compared to prior art methods using catalytic hydrogenation and sep. reduction and cyclization steps, the new method is simpler and safer. In an example, II was refluxed with powdered Fe or Zn in an H2O/AcOH/EtOH mixture, followed by addition of active C, filtration, addition of III to the filtrate, and further boiling, to give after cooling 81% I, pure by chromatog.

IT 90509-02-7P, Dabendazole
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, via zinc or iron reduction of aminonitrobenzene derivative)

RN 90509-02-7 CAPLUS
CN Benzenesulfonic acid, 4-fluoro-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)

L3 ANSWER 20 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L3 ANSWER 21 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1992:503485 CAPLUS
DOCUMENT NUMBER: 117:103485
TITLE: Determination of luxabendazole in biological fluids by high-performance liquid chromatography
AUTHOR(S): Alvarez-Bujidos, M. L.; Ortiz, A.; Balana, R.; Cubria, J. C.; Ordonez, D.; Negro, A.
CORPORATE SOURCE: Dep. Fisiol., Farmacol. Toxicol., Univ. Leon, Leon, E-24071, Spain
SOURCE: Journal of Chromatography (1992), 578(2), 321-6
CODEN: JOCRAM; ISSN: 0021-9673
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Luxabendazole, a new benzimidazole, is a highly potent broad-spectrum anthelmintic. A high-performance liquid chromatog. method has been developed for its determination in serum and urine samples. In order to optimize the clean-up of samples the authors compared two procedures: C18 Sep-Pak cartridges and ultrafiltration through a cellulose membrane with a 30 000 relative mol. mass cut-off. In order to obtain the most suitable mobile phase, the influence of pH and acetonitrile content on the capacity factor (k') was studied. Chromatog. separation and quantification were performed on a reversed-phase column packed with 5-μm Nucleosil C18. The mobile phase was acetonitrile-0.05 M phosphate buffer (pH 7.0), (40:60, volume/volume). The column effluent was monitored by UV-visible spectrophotometry at 290 nm. The method shows good recovery, precision and accuracy. The lower limit of detection for luxabendazole is 15 ng/mL in serum samples and 25 ng/mL in urine samples.

IT 90509-02-7, Luxabendazole
RL: ANT (Analyte); ANST (Analytical study)
(determination of, in urine and blood samples by HPLC)

RN 90509-02-7 CAPLUS
CN Benzenesulfonic acid, 4-fluoro-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



L3 ANSWER 22 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1992:34548 CAPLUS
DOCUMENT NUMBER: 116:34548
TITLE: Antiparasitic compositions containing pyraclobos and benzimidazole for animal use
INVENTOR(S): Parish, Roger; Chapin, Frederic W.; Kono, Yoshiaki; Tsukui, Makoto
PATENT ASSIGNEE(S): SmithKline Beecham Corp., USA; Takeda Chemical Industries, Ltd.
SOURCE: PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9108669	A1	19910627	WO 1990-US6595	19901109
W: AU, BR, CA, HU, JP, KR, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
JP 04009333	A2	19920114	JP 1990-186813	19900713
EP 505389	A1	19920930	EP 1990-917621	19901109
EP 505389	B1	19970514		
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
BR 9007951	A	19921110	BR 1990-7951	19901109
HU 62474	A2	19930528	HU 1992-2055	19901109
JP 05504334	T2	19930708	JP 1991-500559	19901109
AU 654942	B2	19941201	AU 1991-68715	19901109
AT 152879	E	19970515	AT 1990-917621	19901109
ES 2102370	T3	19970801	ES 1990-917621	19901109
ZA 9010174	A	19910925	ZA 1990-10174	19901218
CN 1053549	A	19910807	CN 1990-110426	19901219
CN 1173331	A	19980218	CN 1997-105431	19970526

PRIORITY APPLN. INFO.: JP 1989-330224 A 19891219
JP 1989-338973 A 19891226
JP 1990-113147 A 19900427
JP 1989-330224 19891219
JP 1990-186813 19900713
WO 1990-US6595 W 19901109

OTHER SOURCE(S): MARPAT 116:34548

AB Antiparasitic compns. for animal use contain pyraclofos (I) or related compds. with/without benzimidazole derivs. The compns. are effective in the prevention, treatment, and removal of internal and external parasites, and especially effective in killing benzimidazole-resistant helminths at dosage levels nontoxic to the animals. Thus, worm-free sheep were infested with benzimidazole-resistant Haemonchus contortus, Ostertagia circumcincta, or Trichostrongylus colubr and treated by direct percutaneous intraruminal puncture with 30 mg I and 3.8 mg albendazole/kg. The infestations were effectively controlled.

IT 90509-02-7D, Luxabendazole, mixts. with pyraclofos derivs.
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(antiparasitic activity of)

RN 90509-02-7 CAPLUS

CN Benzenesulfonic acid, 4-fluoro-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)

L3 ANSWER 22 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L3 ANSWER 23 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1991:589757 CAPLUS
DOCUMENT NUMBER: 115:189757
TITLE: Non-aqueous micellar solutions of various drugs
INVENTOR(S): Crooks, Michael John
PATENT ASSIGNEE(S): Australia
SOURCE: Eur. Pat. Appl., 10 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 427582	A2	19910515	EP 1990-402860	19901012
EP 427582	A3	19920812		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
US 5169846	A	19921208	US 1990-595906	19901011
AU 9064533	A1	19910418	AU 1990-64533	19901012
AU 628671	B2	19920917		
ZA 9008165	A	19910828	ZA 1990-8165	19901012

PRIORITY APPLN. INFO.: AU 1989-6807 A 19891012

AB A nonaq. micellar solution for improvement of animal health comprise water-insol. anthelmintics and/or insect growth regulators in an ethoxylated oil or fat surfactant and cosolvents chosen from a group containing DMSO, N-Me pyrrolidone, tetraglycol, and propylene glycol. The system allows poorly water-soluble drugs to enhance their bioavailability and also allows transport of the drugs (especially for insect growth regulators) across the skin. Thus, 5 g albendazole was dispersed in DMSO 10 g and 85 g of ethoxylated castor oil was added while heating to give a clear product for topical administration.

IT 90509-02-7, Luxabendazole
RL: BIOL (Biological study)
(nonaq. solution containing ethoxylated castor oil and methylpyrrolidone and, bioavailability improvement in)

RN 90509-02-7 CAPLUS

CN Benzenesulfonic acid, 4-fluoro-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



agent that destroys parasitic worms.

L3 ANSWER 24 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1991:199108 CAPLUS
DOCUMENT NUMBER: 114:199108
TITLE: Comparative efficacies of commercially available benzimidazoles against Pseudodactylogyrus infestations in eels
AUTHOR(S): Buchmann, K.; Bjerregaard, J.
CORPORATE SOURCE: Dep. Fish Dis., R. Vet. Agric. Univ., Frederiksberg, DK-1870, Den.
SOURCE: Diseases of Aquatic Organisms (1990), 9(2), 117-20
CODEN: DAOREO; ISSN: 0177-5103
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The antiparasitic efficacies of 9 benzimidazoles in com. available formulations were tested (water bath treatments) on small pigmented eels, Anguilla anguilla, exptl. infested by 30 to 140 specimens of Pseudodactylogyrus (Monogenea). Exposure time was 24 h and eels were examined 4 to 5 d post treatment. Mebendazole (Vermox; 1 mg L-1) eradicated all parasites, whereas luxabendazole (pure substance) and albendazole (Valbazen) were 100% effective only at a concentration of 10 mg L-1. Flubendazole (Flubenol), fenbendazole (Panacur) and oxibendazole (Loditac) (10 mg L-1) caused a reduction of the infestation level to a larger extent than did triclabendazole (Fasinex) and parbendazole (Helmatac). Thiabendazole (Equizole), even at a concentration as high as 100 mg L-1, was without effect on Pseudodactylogyrus.

IT 90509-02-7, Luxabendazole
RL: PRP (Properties)
(anthelmintic effect of, in eels infested with Pseudodactylogyrus)

RN 90509-02-7 CAPLUS

CN Benzenesulfonic acid, 4-fluoro-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



L3 ANSWER 25 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1990:551046 CAPLUS
DOCUMENT NUMBER: 113:151046
TITLE: Interaction of anthelmintic residues in cow milk with bacteria and Penicillium roquefortii
AUTHOR(S): Longin-Sauvageon, C.; Beguin, J. C.; Florent, M.
CORPORATE SOURCE: INRA, E. Natl. Vet. Lyon, Marcy-l'Etoile, 69280, Fr.
SOURCE: Lait (1990), 70(1), 37-44
CODEN: LAITAG; ISSN: 0023-7302
DOCUMENT TYPE: Journal
LANGUAGE: French

AB Residues of 9 anthelmintics and their metabolites in milk following administration to cows at doses 1.5-fold recommended levels did not have a neg. effect on bacteria (Streptococcus thermophilus, Bacillus species) and P. roquefortii during cheese manufacture Although lobendazole, albendazole, thiabendazole, luxabendazole, and fenbendazole were active against P. roquefortii in vitro (minimal inhibitory concentration ≤1.56 μg/mL), none of these anthelmintics are likely to hinder cheese manufacture when used under recommended conditions.

IT 90509-02-7, Luxabendazole
RL: BIOL (Biological study)
(Penicillium roquefortii inhibition by, cheese manufacture in relation to)

RN 90509-02-7 CAPLUS
CN Benzenesulfonic acid, 4-fluoro-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



L3 ANSWER 26 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1985:6487 CAPLUS
DOCUMENT NUMBER: 102:6487
TITLE: Substituted phenylsulfonyloxybenzimidazolecarbamates and their anthelminthic use
INVENTOR(S): Roesner, Manfred; Loewe, Heinz; Duewel, Dieter; Kirsch, Reinhard
PATENT ASSIGNEE(S): Hoechst A.-G. , Fed. Rep. Ger.
SOURCE: Ger. Offen., 17 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3247615	A1	19840705	DE 1982-3247615	19821223
HU 32810	O	19840928	HU 1983-4331	19831219
HU 192972	B	19870828		
FI 8304709	A	19840624	FI 1983-4709	19831221
ES 528243	A1	19840801	ES 1983-528243	19831221
EP 115039	A1	19840808	EP 1983-112900	19831221
EP 115039	B1	19880210		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
US 4639463	A	19870127	US 1983-563780	19831221
IL 70520	A1	19880131	IL 1983-70520	19831221
AT 32459	E	19880215	AT 1983-112900	19831221
DK 8305938	A	19840624	DK 1983-5938	19831222
DK 150065	B	19861201		
DK 150065	C	19871026		
NO 8304773	A	19840625	NO 1983-4773	19831222
AU 8322808	A1	19840628	AU 1983-22808	19831222
AU 558902	B2	19870212		
JP 59118774	A2	19840709	JP 1983-241121	19831222
JP 04034545	B4	19920608		
ZA 8309534	A	19840829	ZA 1983-9534	19831222
CA 1199642	A1	19860121	CA 1983-444076	19831222

PRIORITY APPLN. INFO.: DE 1982-3247615 A 19821223
EP 1983-112900 A 19831221
OTHER SOURCE(S): CASREACT 102:6487
GI



I

AB Anthelmintic (no data) title compds. (I; R = substituted Ph; R1 = alkyl) were prepared 2,4-(H2N)(4-FC6H4SO3)C6H3NO2 was hydrogenated over Raney Ni to give the diamine which was cyclocondensed with MeO2CN:C(SMe)NHCO2Me to give I (R = 4-FC6H3, R1 = Me).

IT 90509-02-7P 93624-05-6P 93624-06-7P
93624-07-8P 93624-08-9P 93624-09-0P
93624-10-3P 93624-11-4P 93624-12-5P
93624-13-6P 93624-14-7P
RL: SPN (Synthetic preparation); PREP (Preparation)

L3 ANSWER 26 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
(prepn. of)

RN 90509-02-7 CAPLUS
CN Benzenesulfonic acid, 4-fluoro-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 93624-05-6 CAPLUS
CN Benzenesulfonic acid, 3-(1,1,2,2-tetrafluoroethyl)-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 93624-06-7 CAPLUS
CN Benzenesulfonic acid, 4-ethyl-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 93624-07-8 CAPLUS
CN Benzenesulfonic acid, 4-(1-methylethyl)-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 93624-08-9 CAPLUS
CN Benzenesulfonic acid, 4-propyl-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)

L3 ANSWER 26 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 93624-09-0 CAPLUS
CN Benzenesulfonic acid, 4-cyclohexyl-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 93624-10-3 CAPLUS
CN Benzenesulfonic acid, 3-fluoro-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 93624-11-4 CAPLUS
CN Benzenesulfonic acid, 3,4-difluoro-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 93624-12-5 CAPLUS
CN Benzenesulfonic acid, 4-bromo-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)

L3 ANSWER 26 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 93624-13-6 CAPLUS
CN Benzenesulfonic acid, 2-fluoro-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 93624-14-7 CAPLUS
CN Benzenesulfonic acid, 3,5-bis(trifluoromethyl)-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



L3 ANSWER 27 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 59206-73-4 CAPLUS
CN Benzenesulfonic acid, 3-chloro-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 59206-76-7 CAPLUS
CN Benzenesulfonic acid, 3,5-dichloro-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 59206-79-0 CAPLUS
CN Benzenesulfonic acid, 3-bromo-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 59206-82-5 CAPLUS
CN Carbamic acid, [5-[[(4-methylphenyl)sulfonyl]oxy]-1H-benzimidazol-2-yl]-, methyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 27 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1978:121185 CAPLUS
DOCUMENT NUMBER: 88:121185
TITLE: Anthelmintic 2-carbalkoxyamino-5(6)-phenylsulfonyloxybenzimidazole derivatives
INVENTOR(S): Loewe, Heinz; Urbanietz, Josef; Duwel, Dieter; Kirsch, Reinhard
PATENT ASSIGNEE(S): Hoechst A.-G., Fed. Rep. Ger.
SOURCE: Braz. Pedido PI, 36 pp.
CODEN: BPXXDX
DOCUMENT TYPE: Patent
LANGUAGE: Portuguese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
→	BR 7601238	A	19770906	BR 1976-1238	19760226
PRIORITY APPLN. INFO.:				BR 1976-1238 A	19760226

GI



AB Benzimidazolecarbamates I (R = C1-4 alkyl, R1, R2 = H, OH, C1-4 alkyl, alkoxy, or alkoxycarbonyl, halogen, CF3) were prepared Thus MeSC(:NH)NHCO2Me was treated with 3,4-(H2N)2C6H3O3SPh to give I (R = Me, R1 = R2 = H). MeSC(:NH)NHCO2Me was prepared in situ by treating MeSC(:NH)NH2.H2SO4 with ClCO2Me. 3,4-(H2N)2C6H3O3SPh was obtained by treating 3,4-O2N(H2N)C6H3OH with PhSO2Cl and reducing 3,4-O2N(H2N)C6H3O3SPh.

IT **59206-66-5P 59206-70-1P 59206-73-4P**
59206-76-7P 59206-79-0P 59206-82-5P
59206-85-8P 59206-88-1P 62889-94-5P
62889-95-6P 62889-96-7P 62889-97-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 59206-66-5 CAPLUS
CN Carbamic acid, [5-[(phenylsulfonyl)oxy]-1H-benzimidazol-2-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 59206-70-1 CAPLUS
CN Benzenesulfonic acid, 4-chloro-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)

L3 ANSWER 27 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 59206-85-8 CAPLUS
CN Benzenesulfonic acid, 3-methyl-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 59206-88-1 CAPLUS
CN Benzenesulfonic acid, 3-(trifluoromethyl)-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 62889-94-5 CAPLUS
CN Benzenesulfonic acid, 3,4-dichloro-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 62889-95-6 CAPLUS
CN Benzenesulfonic acid, 3-(trifluoromethyl)-, 2-[(ethoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)

L3 ANSWER 27 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 62889-96-7 CAPLUS
CN Benzenesulfonic acid, 3-(trifluoromethyl)-, 2-[[(1-methylethoxy)carbonyl]amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 62889-97-8 CAPLUS
CN Benzenesulfonic acid, 3-(trifluoromethyl)-, 2-[[(2-methylpropoxy)carbonyl]amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



L3 ANSWER 28 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1977:423283 CAPLUS
DOCUMENT NUMBER: 87:23283
TITLE: 2-(Carbalkoxyamino)-5(6)-(phenylsulfonyloxy)benzimidazoles with anthelminthic activity
INVENTOR(S): Loeve, Heinz; Urbanietz, Josef; Duewel, Dieter; Kirsch, Reinhard
PATENT ASSIGNEE(S): Hoechst A.-G., Fed. Rep. Ger.
SOURCE: Ger. Offen., 14 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2541752	A1	19770324	DE 1975-2541752	19750919
JP 59014027	B4	19840402	JP 1976-20235	19760227
NL 7610192	A	19770322	NL 1976-10192	19760914
FI 7602653	A	19770320	FI 1976-2653	19760916
SE 7610310	A	19770320	SE 1976-10310	19760916
HU 172484	P	19780928	HU 1976-HO1929	19760916
DK 7604198	A	19770320	DK 1976-4198	19760917
DK 141550	B	19800421		
DK 141550	C	19801006		
NO 7603196	A	19770322	NO 1976-3196	19760917
CA 1069909	A1	19800115	CA 1976-261425	19760917
AT 7606908	A	19800215	AT 1976-6908	19760917
AT 358575	B	19800925		
CH 619938	A	19801031	CH 1976-11820	19760917

PRIORITY APPLN. INFO.: DE 1975-2541752 19750919
GI



I

AB Anthelmintic benzimidazolecarbamates (I; Rn = H, 3-Cl, 4-Cl, 3-Br, 3-Me, 4-Me, 3,4-Cl2, 3,5-Cl2, 3-F3C; R1 = Me, Et, Me2CH, Me2CHCH2) are prepared by reaction of the appropriate benzenesulfonyl chloride with 5-hydroxybenzimidazolecarbamates. Thus, reaction of 5.15 g 2-(carbomethoxyamino)-5-hydroxybenzimidazole with 4.4 g PhSO2Cl in Me2CO in presence of Et3N gives after 10 h at room temperature 6.2 g I (Rn = H, R1 = Me).
IT **59206-66-5P 59206-70-1P 59206-73-4P**
59206-76-7P 59206-79-0P 59206-82-5P
59206-85-8P 59206-88-1P 62889-94-5P
62889-95-6P 62889-96-7P 62889-97-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and anthelmintic activity of)
RN 59206-66-5 CAPLUS
CN Carbamic acid, [5-[(phenylsulfonyl)oxy]-1H-benzimidazol-2-yl]-, methyl

L3 ANSWER 28 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
ester (9CI) (CA INDEX NAME)



RN 59206-70-1 CAPLUS
CN Benzenesulfonic acid, 4-chloro-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 59206-73-4 CAPLUS
CN Benzenesulfonic acid, 3-chloro-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 59206-76-7 CAPLUS
CN Benzenesulfonic acid, 3,5-dichloro-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 59206-79-0 CAPLUS
CN Benzenesulfonic acid, 3-bromo-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)

L3 ANSWER 28 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 59206-82-5 CAPLUS
CN Carbamic acid, [5-[[(4-methylphenyl)sulfonyl]oxy]-1H-benzimidazol-2-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 59206-85-8 CAPLUS
CN Benzenesulfonic acid, 3-methyl-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 59206-88-1 CAPLUS
CN Benzenesulfonic acid, 3-(trifluoromethyl)-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 62889-94-5 CAPLUS
CN Benzenesulfonic acid, 3,4-dichloro-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)

L3 ANSWER 28 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 62889-95-6 CAPLUS
CN Benzenesulfonic acid, 3-(trifluoromethyl)-, 2-[(ethoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 62889-96-7 CAPLUS
CN Benzenesulfonic acid, 3-(trifluoromethyl)-, 2-[[(1-methylethoxy)carbonyl]amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 62889-97-8 CAPLUS
CN Benzenesulfonic acid, 3-(trifluoromethyl)-, 2-[[(2-methylpropoxy)carbonyl]amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



L3 ANSWER 29 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1977:405976 CAPLUS
DOCUMENT NUMBER: 87:5976
TITLE: 2-Carbalkoxyaminobenzimidazole derivatives with anthelmintic activity
INVENTOR(S): Loewe, Heinz; Urbanietz, Josef; Duewel, Dieter; Kirsch, Reinhard
PATENT ASSIGNEE(S): Hoechst A.-G., Fed. Rep. Ger.
SOURCE: Ger. Offen., 19 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2541751	A1	19770324	DE 1975-2541751	19750919
NL 7610191	A	19770322	NL 1976-10191	19760914
FI 7602654	A	19770320	FI 1976-2654	19760916
SE 7610311	A	19770320	SE 1976-10311	19760916
DK 7604199	A	19770320	DK 1976-4199	19760917
NO 7603197	A	19770322	NO 1976-3197	19760917
CH 605822	A	19781013	CH 1976-11822	19760917
AT 7606909	A	19791015	AT 1976-6909	19760917
AT 356651	B	19800512		
CA 1069908	A1	19800115	CA 1976-261424	19760917

PRIORITY APPLN. INFO.: DE 1975-2541751 A 19750919
GI



I

AB Benzimidazolecarbamates I (R = Me, Et, Pr, Bu; Rln = e.g. H, 3-Br, 3-Cl, 4-Cl, 3,5-Cl2, 3-Me, 4-Me, 3-MeO, 3-F3C; X = OSO2, SO2O), useful as anthelmintics (no data), are prepared by treatment of the appropriate 1H-2,1,4-benzothiadiazine-3-carbamates with Ph3P. Thus, treatment of 5 g Ph 3-(carbomethoxyamino)-1H-2,1,4-benzothiadiazine-7-sulfonate with 7.5 g Ph3P 3 h in refluxing CHCl3 gives 3.2 g I (R = Me, Rln = H, X = OSO2).

IT **59206-66-5P 59206-70-1P 59206-73-4P**
59206-76-7P 59206-79-0P 59206-82-5P
59206-85-8P 59206-88-1P 62889-94-5P
62889-95-6P 62889-96-7P 62889-97-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 59206-66-5 CAPLUS
CN Carbamic acid, [5-[(phenylsulfonyl)oxy]-1H-benzimidazol-2-yl]-, methyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 29 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 59206-70-1 CAPLUS
CN Benzenesulfonic acid, 4-chloro-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 59206-73-4 CAPLUS
CN Benzenesulfonic acid, 3-chloro-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 59206-76-7 CAPLUS
CN Benzenesulfonic acid, 3,5-dichloro-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 59206-79-0 CAPLUS
CN Benzenesulfonic acid, 3-bromo-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)

L3 ANSWER 29 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 59206-82-5 CAPLUS
CN Carbamic acid, [5-[[(4-methylphenyl)sulfonyl]oxy]-1H-benzimidazol-2-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 59206-85-8 CAPLUS
CN Benzenesulfonic acid, 3-methyl-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 59206-88-1 CAPLUS
CN Benzenesulfonic acid, 3-(trifluoromethyl)-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 62889-94-5 CAPLUS
CN Benzenesulfonic acid, 3,4-dichloro-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)

L3 ANSWER 29 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 62889-95-6 CAPLUS
CN Benzenesulfonic acid, 3-(trifluoromethyl)-, 2-[(ethoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 62889-96-7 CAPLUS
CN Benzenesulfonic acid, 3-(trifluoromethyl)-, 2-[[(1-methylethoxy)carbonyl]amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 62889-97-8 CAPLUS
CN Benzenesulfonic acid, 3-(trifluoromethyl)-, 2-[[(2-methylpropoxy)carbonyl]amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



L3 ANSWER 30 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1976:180222 CAPLUS
DOCUMENT NUMBER: 84:180222
TITLE: Anthelmintic 2-carbalkoxyamino-5(6)-phenylsulfonyloxybenzimidazoles
INVENTOR(S): Loewe, Heinz; Urbanietz, Josef; Duewel, Dieter; Kirsch, Reinhard
PATENT ASSIGNEE(S): Hoechst A.-G., Fed. Rep. Ger.
SOURCE: Ger. Offen., 24 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2441201	A1	19760311	DE 1974-2441201	19740828
DE 2441201	C2	19860807		
CS 196278	P	19800331	CS 1975-5619	19750815
NL 7509957	A	19760302	NL 1975-9957	19750822
NL 187208	B	19910201		
NL 187208	C	19910701		
FR 2282881	A1	19760326	FR 1975-26015	19750822
FR 2282881	B1	19800430		
ES 440386	A1	19770601	ES 1975-440386	19750822
SE 7509442	A	19760301	SE 1975-9442	19750825
SE 417509	B	19810323		
SE 417509	C	19810709		
FI 7502397	A	19760229	FI 1975-2397	19750826
FI 60203	B	19810831		
FI 60203	C	19811210		
DD 124978	C	19770323	DD 1975-188034	19750826
GB 1472718	A	19770504	GB 1975-35218	19750826
IL 47997	A1	19781031	IL 1975-47997	19750826
CH 613195	A	19790914	CH 1975-11068	19750826
DK 7503848	A	19760229	DK 1975-3848	19750827
DK 136188	B	19770829		
NO 7502944	A	19760302	NO 1975-2944	19750827
NO 140591	C	19791003		
NO 140591	B	19790625		
ZA 7505486	A	19760728	ZA 1975-5486	19750827
SU 576044	D	19771005	SU 1975-2167451	19750827
AT 347935	B	19790125	AT 1975-6637	19750827
CA 1059135	A1	19790724	CA 1975-234272	19750827
BE 832859	A1	19760301	BE 1975-159560	19750828
JP 51048665	A2	19760426	JP 1975-103563	19750828
JP 59010350	B4	19840308		
CS 196279	P	19800331	CS 1978-6320	19780829
CS 196280	P	19800331	CS 1978-6321	19780829
CS 196281	P	19800331	CS 1978-6322	19780829

PRIORITY APPLN. INFO.: DE 1974-2441201 A 19740828
CS 1975-5619 19750815

GI

L3 ANSWER 30 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



I

AB Phenylsulfonyloxybenzimidazole I (R = H, 4-Cl, 3-Cl, 3-Br, 4-Me, 3-Me, 3-CF3, 3,5-Cl2) were prepared by treating 3,4-O2N(H2N)C6H3OH with RC6H4SO2Cl, reducing 3,4-O2N(H2N)C6H3O3SC6H4R, and condensing 3,4-(H2N)2C6H3O3SC6H4R with HN:C(SMe)NHCO2Me, prepared by treating HN:C(SMe)NH2 with ClCO2Me.

IT 59206-66-5P 59206-70-1P 59206-73-4P
59206-76-7P 59206-79-0P 59206-82-5P
59206-85-8P 59206-88-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 59206-66-5 CAPLUS
CN Carbamic acid, [5-[(phenylsulfonyl)oxy]-1H-benzimidazol-2-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 59206-70-1 CAPLUS
CN Benzenesulfonic acid, 4-chloro-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 59206-73-4 CAPLUS
CN Benzenesulfonic acid, 3-chloro-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 59206-76-7 CAPLUS
CN Benzenesulfonic acid, 3,5-dichloro-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 59206-79-0 CAPLUS
CN Benzenesulfonic acid, 3-bromo-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 59206-82-5 CAPLUS
CN Carbamic acid, [5-[[(4-methylphenyl)sulfonyl]oxy]-1H-benzimidazol-2-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 59206-85-8 CAPLUS
CN Benzenesulfonic acid, 3-methyl-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



RN 59206-88-1 CAPLUS
CN Benzenesulfonic acid, 3-(trifluoromethyl)-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl ester (9CI) (CA INDEX NAME)



/

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	148.65	310.19

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-21.90	-21.90

STN INTERNATIONAL LOGOFF AT 15:50:41 ON 10 FEB 2005